“Tim’s wealth of experience and industry knowledge has made him a key addition to the ITI team," remarked Bill Hearl, ITI’s CEO and Founder.
Hershey, PA & Rockville, MD (PRWEB) February 10, 2015
Immunomic Therapeutics, Inc. (ITI) announced today that Timothy Coleman Ph.D. has joined the company to further develop a comprehensive growth plan and maximize the value of the lab facilities in Hershey, PA and Rockville, MD.
Dr. Coleman comes to ITI with broad experience in the life sciences industry. Most recently, he was Senior Director of New Product Development at SeraCare Life Sciences, Gaithersburg, MD; prior to that, Dr. Coleman worked at Lonza Bioscience, Inc., Walkersville, MD where he held leadership roles in innovative product development and quality control.
At ITI, Dr. Coleman will have an assortment of responsibilities including expanding the capabilities of the company’s Hershey, PA operation along with leading ITI’s CMC Team in the new collaborative effort with Astellas Pharma. He will certainly facilitate the company’s rapid growth position in the biotechnology industry.
“Tim’s wealth of experience and industry knowledge has made him a key addition to the ITI team. Our new relationship with Astellas will require an increased commitment to operational issues as we move closer to product commercialization. We view his appointment as an indicator of our commitment to becoming a pioneering leader in our industry,” remarked Bill Hearl, ITI’s CEO and Founder.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases.